Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent reduction in prostaglandin synthesis; tenoxicam belongs to the oxicam class of nonsteroidal antiinflammatory drugs and shows high plasma protein binding (>99%), low aqueous solubility, and a long elimination half life (approximately 60 to 80 hours) that supports once daily dosing in most regimens. Pharmacokinetic and metabolic characteristics include extensive hepatic metabolism (predominantly via oxidative pathways that involve CYP2C9), biliary and renal excretion of metabolites, and typical onset of analgesic effect within one hour of oral administration. From a formulation and analytical perspective the API is handled as a crystalline, weakly acidic compound where control of polymorphic form, residual solvents, heavy metals, and related substances is important for stability and consistent bioavailability.
Parent: Tenoxicam
Parent: Tenoxicam
Quality control for tenoxicam API and finished products routinely monitors specific known related substances, general degradants, and process-related impurities with typical acceptance criteria used in manufacturing and pharmacopeial contexts; commonly specified limits are individual identified impurities not more than 0.05 to 0.5 percent (w/w) depending on qualification status, total impurities not more than 1.0 percent (w/w), and reporting thresholds for unknown impurities around 0.05 percent. Typical related substances that are monitored include hydroxy and desmethyl derivatives, the N-oxide analogue, trace amounts of residual starting materials from the benzothiazine/thieno-thiazine synthetic route, plus common degradation products formed under oxidative or hydrolytic stress. Additional quality limits commonly applied are residual solvents (for example methanol typically limited to 3000 ppm or less, class 2 solvent limits applied as appropriate), water content controlled per specification (often below 2.0 percent), and heavy metals below 20 ppm unless tighter limits are required by local regulation; specific impurity identification and limits should follow the product master file and relevant pharmacopeial monographs.
Tenoxicam is used primarily as a nonsteroidal antiinflammatory drug to relieve pain and inflammation in musculoskeletal conditions such as osteoarthritis and to control acute pain; dosing and duration depend on indication, patient factors, and local prescribing information.
Strength depends on dose and pharmacology rather than a simple one to one comparison; tenoxicam is more potent on a milligram basis and has a much longer half life permitting once daily dosing, whereas ibuprofen requires multiple daily doses for sustained effect; choice between them depends on clinical context, onset requirement, safety profile, and physician judgment.
Tenoxicam is not classified as a selective COX-2 inhibitor; it inhibits cyclooxygenase enzymes and reduces prostaglandin synthesis with activity against both COX-1 and COX-2, although the degree of selectivity is modest and differs from drugs designed to be COX-2 selective.
Both are oxicam NSAIDs but differ in pharmacokinetics and selectivity: tenoxicam has a longer elimination half life (approximately 60 to 80 hours) allowing once daily dosing and very high protein binding, whereas meloxicam has a shorter half life (about 15 to 20 hours) and shows greater preferential inhibition of COX-2 relative to COX-1, which can influence tolerability and gastrointestinal risk; dosing regimens, approved indications, and specific safety profiles also differ, so selection should be guided by clinical indication and individual patient factors.
